Confirm
– Expansion of management team with proven leader in cardiovascular disease supports advancement of CLEAR Outcomes trial and ESPERION therapeutic pipeline –
ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) ESPERION ( ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and Chief Executive Officer. Dr. Foody brings more than 20 years of experience in academic and preventive cardiology to ESPERION.
“Dr. Foody is a global expert with extensive clinical and medical experience in preventive cardiology, global medical development and medical affairs, which adds greatly to the depth of our management team,” said Sheldon Koenig, President and Chief Executive Officer of ESPERION. “JoAnne joins ESPERION at a critical period for the Company as we continue to drive towards the completion of our landmark CLEAR Out
ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AliveCor, AstraZeneca bring non-invasive potassium monitoring solutions
AliveCor, AstraZeneca bring non-invasive potassium monitoring solutions
17 February 2021 | News
Source credit: Shutterstock
AliveCor, the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, has announced a new collaboration with AstraZeneca, a global science-led biopharmaceutical company, to research new disease management solutions in cardiovascular, renal, and metabolism (CVRM) therapeutic areas.
The collaboration will translate AliveCor s potassium detection technology and science, which enables potassium measurement outside of blood draws, into real-world disease management applications and solutions.
The cross-industry collaboration expands the research and development of AliveCor s Kardia-K AI platform, which received ‘Breakthrough Device Designation’ status from the FDA to screen for elevated levels of blood potassium. Kardia-K is being built using Alive